Concordian International appoints Tzhak Krinsky and Francis Perier, Jr. as members of Board of Directors

Concordian International announced that they have Itzhak Krinsky, PhD. and Francis (Frank) Perier, Jr. as members of Board of Directors. After this appointment the Board will consist of seven members, six of whom are independent.

Concordia Non-Executive Chairman, Jordan Kupinsky said that they are pleased to welcome Itzhak and Frank to the Concordia Board of Directors, and believe their pharmaceutical and financial experience will help the Company through this critical transformation period in our corporate lifecycle. They believe that their combination of domestic and global business experience will be a significant asset to the Board. They both have strong track records as trusted leaders in the pharmaceutical industry and bring a wealth of knowledge to their Company. He look forward to leveraging their expertise as they focus on stabilizing Concordia’s business and completing the Company’s longer-term growth strategy.

Mr. Krinsky brings extensive global pharmaceutical, investment banking, and M&A experience to Concordia. He has been with Teva Pharmaceutical Industries for more than 10 years. As Executive Vice President of Corporate Business Development, he led more than 30 M&A transactions for the company. In his most recent role, Mr. Krinsky served as Chairman of Teva Japan and Chairman of Teva South Korea, where he was responsible for overseeing Teva’s pharmaceutical businesses in both countries. In 2014, he was named by SCRIP as one of the top 100 Global Leaders in the Pharmaceutical Industry. Prior to joining Teva, Mr. Krinsky served as Managing Director at Deutsche Bank, the Silverfern Group and Trenwith Securities, LLC, investment banks in New York City. He holds Bachelor, and Master of Arts in Economics degrees from Tel Aviv University and a Doctorate in Economics from McMaster University.

Mr. Perier has more than 18 years of experience in the pharmaceutical and healthcare industries, including senior roles at two major pharmaceutical companies. Most recently, he served as CFO of Forest Laboratories for 10 years, where he played a significant leadership role in overseeing multiple financial transactions. Prior to Forest Laboratories, He served in several senior financial positions at Bristol-Myers Squibb (BMS), including four years as Vice President of Finance, Planning, Business Development and Information Technology in the ConvaTec Division, where he was responsible for the execution of the company’s strategic plan and business objectives. Prior to his time at BMS, Mr. Perier served in multiple roles at Deloitte & Touche LLP from 1981 to 1996. He holds a Master of Business Administration (MBA) from New York University’s Leonard N. Stern School of Business and a Bachelor of Science in Accounting from Villanova University. He is also a Certified Public Accountant.